FDA Clearance Tracker · K082947
LENSX 550 LASER SYSTEM
Last checked: Nov 20, 2026Latest source record: Aug 14, 2009 (this decision)Source: openFDAMethods & limitations
Decided
Aug 14, 2009
Substantially Equivalent
Time to decision
316 days
Received Oct 2, 2008. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K082947
- Device name
- LENSX 550 LASER SYSTEM
- Applicant
- Lensx Lasers, Inc.
- Applicant location
- Laguna Beach, CA
- Received
- Oct 2, 2008
- Decided
- Aug 14, 2009
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Ophthalmic Femtosecond Laser (OOE)
- Device class
- Class II
- Regulation
- 21 CFR 886.4390
- Specialty
- Ophthalmology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code OOE (Ophthalmic Femtosecond Laser).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K082947
- The applicant filed a summary instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Lensx Lasers, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.